JPRN-UMIN000004494已完成未知
Phase I/II clinical trila by gemcitabine+CDDP- or S-1- combined peptide vaccination for metastatic biliary tract cancers - Clinical trila by chemotherapy-combined peptide vaccination for metastatic biliary tract cancers
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients -obtains previous radiation therapy for biliary tract cancers. -obtains brain metastasis not manipulated. -obtains active duplicated neoplastic diseases. -obtains co-morbidity as follows; intestinal paralysis, intestinal obstruction, diabetes mellitus, hypertension, angina pectoris, livet cirrhosis, pneumonitis, emphysema. -is HIV-positiveness -has past history of severe allergic reaction for gemcitabine, cisplatin, or TS-1. -obtains ascites or pleural effusion that needs treatment. -has severe diarrhea or GI bleeding. -has treatment by frucitosine -is pregnat or can be pregnant. -desires partners pregnancy. -has HLA-A genotype opened.
研究者
相似试验
已完成
1 期
phase I/II trial of Gemcitabine/CDDP/S-1 combination chemotherapy for locally advanced or metastatic biliary tract cancerocally advanced or metastatic biliary tract cancerJPRN-UMIN000007563Keio University, School of Medicine, Div. of Gastroenterology, Dept.of Internal Medicine36
进行中（未招募）
1 期
A Phase III Randomised Trial of Gemcitabine plus Docetaxel followed by Doxorubicin versus observation for uterus-limited, high grade uterine leiomyosarcomaPatients with high risk uterine LMS, FIGO stage I (confined to corpus +/- cervix).MedDRA version: 14.1 Level: PT Classification code 10046799 Term: Uterine leiomyosarcoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002852-17-GBEORTC216
已完成
2 期
Phase II trial of GDP therapy (gemcitabine, cisplatin and dexamethasone) in patients with refractory or recurrence non-Hodgkin's lymphoma having a history of more than 2 regimens.non-Hodgkin's lymphomaJPRN-UMIN000013588Kyoto Prefectural University of Medicine Department of Hematology and Oncology,30
招募中
2 期
Biliary tract cancer cross-over studybiliary tract cancerJPRN-jRCT1041230014Yamashita Tatsuya50
进行中（未招募）
不适用
Phase II study with gemcitabine/docetaxel fist line in women with metastatic breast cancer. - SF2gem/taxOncologic patients only.MedDRA version: 6.1Level: PTClassification code 10055113EUCTR2006-000165-10-ITA.S.L. 2 SAVONA70